Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

by Web Master, Benzinga Editor
October 17, 2011 11:29 AM | 7 seconds read |
Roche's purchase of Anadys provides the third drug in what may be the first all-oral hepatits C regimen to start late-stage trials.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!